BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 36117156)

  • 1. Comprehensive analysis reveals the potential value of inflammatory response genes in the prognosis, immunity, and drug sensitivity of lung adenocarcinoma.
    Song C; Pan S; Li D; Hao B; Lu Z; Lai K; Li N; Geng Q
    BMC Med Genomics; 2022 Sep; 15(1):198. PubMed ID: 36117156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an invasion score based on metastasis-related pathway activity profiles for identifying invasive molecular subtypes of lung adenocarcinoma.
    Han T; Liu Y; Zhou J; Guo J; Xing Y; Xie J; Bai Y; Wu J; Hu D
    Sci Rep; 2024 Jan; 14(1):1692. PubMed ID: 38243040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of an inflammatory response signature associated with prognostic stratification and drug sensitivity in lung adenocarcinoma.
    Song C; Lu Z; Lai K; Li D; Hao B; Xu C; Pan S; Li N; Geng Q
    Sci Rep; 2022 Jun; 12(1):10110. PubMed ID: 35710585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of four metabolic subtypes and key prognostic markers in lung adenocarcinoma based on glycolytic and glutaminolytic pathways.
    Zhang J; Wang X; Song C; Li Q
    BMC Cancer; 2023 Feb; 23(1):152. PubMed ID: 36782138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of a Machine Learning Prognostic Model of m5C Related immune Genes in Lung Adenocarcinoma.
    Cao X; Ji Y; Li J; Liu Z; Chen C
    Cancer Control; 2024; 31():10732748241237414. PubMed ID: 38537151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
    Chen M; Wang X; Wang W; Gui X; Li Z
    Front Immunol; 2022; 13():829057. PubMed ID: 35833114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
    Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
    Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting lung adenocarcinoma prognosis, immune escape, and pharmacomic profile from arginine and proline-related genes.
    Wang Z; Zhang J; Shi S; Ma H; Wang D; Zuo C; Zhang Q; Lian C
    Sci Rep; 2023 Sep; 13(1):15198. PubMed ID: 37709932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid metabolism-related gene prognostic index (LMRGPI) reveals distinct prognosis and treatment patterns for patients with early-stage pulmonary adenocarcinoma.
    Jiang A; Chen X; Zheng H; Liu N; Ding Q; Li Y; Fan C; Fu X; Liang X; Tian T; Ruan Z; Yao Y
    Int J Med Sci; 2022; 19(4):711-728. PubMed ID: 35582412
    [No Abstract]   [Full Text] [Related]  

  • 17. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
    Yang Q; Zhu W; Gong H
    Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses.
    Liu Y; Zhang X; Pang Z; Wang Y; Zheng H; Wang G; Wang K; Du J
    Aging (Albany NY); 2024 May; 16(10):8772-8809. PubMed ID: 38771130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma.
    Wang H; Wang X; Xu L; Cao H; Zhang J
    Cancer Med; 2021 Dec; 10(24):9058-9077. PubMed ID: 34734491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.